Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2017 1
2019 5
2020 4
2021 1
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Defining 'T cell exhaustion'.
Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, Lynn RC, Philip M, Rao A, Restifo NP, Schietinger A, Schumacher TN, Schwartzberg PL, Sharpe AH, Speiser DE, Wherry EJ, Youngblood BA, Zehn D. Blank CU, et al. Among authors: youngblood ba. Nat Rev Immunol. 2019 Nov;19(11):665-674. doi: 10.1038/s41577-019-0221-9. Epub 2019 Sep 30. Nat Rev Immunol. 2019. PMID: 31570879 Free PMC article. Review.
Functional T cells are capable of supernumerary cell division and longevity.
Soerens AG, Künzli M, Quarnstrom CF, Scott MC, Swanson L, Locquiao JJ, Ghoneim HE, Zehn D, Youngblood B, Vezys V, Masopust D. Soerens AG, et al. Among authors: youngblood b. Nature. 2023 Feb;614(7949):762-766. doi: 10.1038/s41586-022-05626-9. Epub 2023 Jan 18. Nature. 2023. PMID: 36653453
Two subsets of stem-like CD8+ memory T cell progenitors with distinct fate commitments in humans.
Galletti G, De Simone G, Mazza EMC, Puccio S, Mezzanotte C, Bi TM, Davydov AN, Metsger M, Scamardella E, Alvisi G, De Paoli F, Zanon V, Scarpa A, Camisa B, Colombo FS, Anselmo A, Peano C, Polletti S, Mavilio D, Gattinoni L, Boi SK, Youngblood BA, Jones RE, Baird DM, Gostick E, Llewellyn-Lacey S, Ladell K, Price DA, Chudakov DM, Newell EW, Casucci M, Lugli E. Galletti G, et al. Among authors: youngblood ba. Nat Immunol. 2020 Dec;21(12):1552-1562. doi: 10.1038/s41590-020-0791-5. Epub 2020 Oct 12. Nat Immunol. 2020. PMID: 33046887 Free PMC article.
TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection.
Alfei F, Kanev K, Hofmann M, Wu M, Ghoneim HE, Roelli P, Utzschneider DT, von Hoesslin M, Cullen JG, Fan Y, Eisenberg V, Wohlleber D, Steiger K, Merkler D, Delorenzi M, Knolle PA, Cohen CJ, Thimme R, Youngblood B, Zehn D. Alfei F, et al. Among authors: youngblood b. Nature. 2019 Jul;571(7764):265-269. doi: 10.1038/s41586-019-1326-9. Epub 2019 Jun 17. Nature. 2019. PMID: 31207605
Defining the Molecular Hallmarks of T-Cell Memory.
Zebley CC, Akondy RS, Youngblood BA, Kissick HT. Zebley CC, et al. Among authors: youngblood ba. Cold Spring Harb Perspect Biol. 2022 Mar 1;14(3):a037804. doi: 10.1101/cshperspect.a037804. Cold Spring Harb Perspect Biol. 2022. PMID: 34127444 Free PMC article. Review.
MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects.
Verma V, Jafarzadeh N, Boi S, Kundu S, Jiang Z, Fan Y, Lopez J, Nandre R, Zeng P, Alolaqi F, Ahmad S, Gaur P, Barry ST, Valge-Archer VE, Smith PD, Banchereau J, Mkrtichyan M, Youngblood B, Rodriguez PC, Gupta S, Khleif SN. Verma V, et al. Among authors: youngblood b. Nat Immunol. 2021 Jan;22(1):53-66. doi: 10.1038/s41590-020-00818-9. Epub 2020 Nov 23. Nat Immunol. 2021. PMID: 33230330 Free PMC article.
Stem, Effector, and Hybrid States of Memory CD8+ T Cells.
Lugli E, Galletti G, Boi SK, Youngblood BA. Lugli E, et al. Among authors: youngblood ba. Trends Immunol. 2020 Jan;41(1):17-28. doi: 10.1016/j.it.2019.11.004. Epub 2019 Dec 4. Trends Immunol. 2020. PMID: 31810790 Free PMC article. Review.
Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL.
Talleur AC, Qudeimat A, Métais JY, Langfitt D, Mamcarz E, Crawford JC, Huang S, Cheng C, Hurley C, Madden R, Sharma A, Suliman A, Srinivasan A, Velasquez MP, Obeng EA, Willis C, Akel S, Karol SE, Inaba H, Bragg A, Zheng W, Zhou SM, Schell S, Tuggle-Brown M, Cullins D, Patil SL, Li Y, Thomas PG, Zebley C, Youngblood B, Pui CH, Lockey T, Geiger TL, Meagher MM, Triplett BM, Gottschalk S. Talleur AC, et al. Among authors: youngblood b. Blood Adv. 2022 Nov 8;6(21):5737-5749. doi: 10.1182/bloodadvances.2021006293. Blood Adv. 2022. PMID: 35446934 Free PMC article. Clinical Trial.
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.
O'Connell CL, Baer MR, Ørskov AD, Saini SK, Duong VH, Kropf P, Hansen JW, Tsao-Wei D, Jang HS, Emadi A, Holmberg-Thyden S, Cowland J, Brinker BT, Horwood K, Burgos R, Hostetter G, Youngblood BA, Hadrup SR, Issa JP, Jones P, Baylin SB, Siddiqi I, Grønbaek K. O'Connell CL, et al. Among authors: youngblood ba. Clin Cancer Res. 2022 Dec 15;28(24):5306-5316. doi: 10.1158/1078-0432.CCR-22-1810. Clin Cancer Res. 2022. PMID: 36222848 Free PMC article. Clinical Trial.
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.
Baer MR, Kogan AA, Bentzen SM, Mi T, Lapidus RG, Duong VH, Emadi A, Niyongere S, O'Connell CL, Youngblood BA, Baylin SB, Rassool FV. Baer MR, et al. Among authors: youngblood ba. Clin Cancer Res. 2022 Apr 1;28(7):1313-1322. doi: 10.1158/1078-0432.CCR-21-3729. Clin Cancer Res. 2022. PMID: 35091444 Free PMC article. Clinical Trial.
16 results